Article Details
Retrieved on: 2025-07-16 20:54:01
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Cue Biopharma, Inc. Reports New Complete Response and Confirms 50% Overall Response Rate in Ongoing Phase 1 Trial of CUE-101 and Pembrolizumab in ...
Article found on: www.marketscreener.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here